Titre
Background Paper Change Pain (For internal use only)
Auteur
redactie
Langue
néerlandais
Éditeur
GRUNENTHAL Achen
Prix
€ 24,60
Détails
grote paperback 110pp. in goede staat, opstap voor nieuw pijnbestrijdingsmiddel (schaars)
Plus d'informations
Dear colleague,
we welcome you to an important part of the Integrated Prelaunch Campaign (IPLC) for our new productPalexia - the Cange Pain Background Paper
Grünenthal
From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Unbalanced scales.svg
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (May 2020) (Learn how and when to remove this template message)
Grünenthal GmbH
Official logo of Grünenthal
Aachen Grünenthal.jpg
Headquarters of Grünenthal
Formerly
Chemie Grünenthal
Type
private company (GmbH)
Industry pharmaceutical
Founded 1946; 74 years ago in Stolberg, North Rhine-Westphalia, Germany
Founder Hermann Wirtz, Sr. [de]
Headquarters Aachen, North Rhine-Westphalia, Germany
Number of locations
29 (commercial presence)
5 (manufacturing sites)
Areas served
+100 countries worldwide
Key people
Gabriel Baertschi (CEO)
Fabian Raschke (CFO)
Mark Fladrich (CCO)
Jan Adams (CSO)
Products
Tapentadol
Thalidomide
Tramadol
etc.
Revenue Increase €1.4 billion (2019)
Owner Wirtz family
Number of employees
Decrease 4,700 (2019)
Website www.grunenthal.com
Footnotes / references
Corporate Profile
Grünenthal is a pharmaceutical company headquartered in Aachen in Germany. The company was founded in 1946 as Chemie Grünenthal and has been continuously family-owned. The company was the first to introduce penicillin into the German market in the postwar period, after the Allied Control Council lifted its ban.
Grünenthal became infamous in the 1950s and 1960s for the development and sale of the teratogenic drug thalidomide, marketed as the sleeping pill Contergan and promoted as a morning sickness preventative. Thalidomide caused severe birth defects, miscarriages, and other severe health problems. Though these side effects were proven conclusively in 1959,[1] and 1962,[2] Grünenthal continued marketing the drug well into the 1970s and 1980s.[3]
The company generates more than 50 percent of its income with pain medications such as the drug Tramadol. The company has two offices in Germany as well as subsidiaries in Europe, Latin America, the US, and China. In November 2016, the company acquired Thar Pharmaceuticals [4] and in 2018 Averitas Pharma.[5]
we welcome you to an important part of the Integrated Prelaunch Campaign (IPLC) for our new productPalexia - the Cange Pain Background Paper
Grünenthal
From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Unbalanced scales.svg
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (May 2020) (Learn how and when to remove this template message)
Grünenthal GmbH
Official logo of Grünenthal
Aachen Grünenthal.jpg
Headquarters of Grünenthal
Formerly
Chemie Grünenthal
Type
private company (GmbH)
Industry pharmaceutical
Founded 1946; 74 years ago in Stolberg, North Rhine-Westphalia, Germany
Founder Hermann Wirtz, Sr. [de]
Headquarters Aachen, North Rhine-Westphalia, Germany
Number of locations
29 (commercial presence)
5 (manufacturing sites)
Areas served
+100 countries worldwide
Key people
Gabriel Baertschi (CEO)
Fabian Raschke (CFO)
Mark Fladrich (CCO)
Jan Adams (CSO)
Products
Tapentadol
Thalidomide
Tramadol
etc.
Revenue Increase €1.4 billion (2019)
Owner Wirtz family
Number of employees
Decrease 4,700 (2019)
Website www.grunenthal.com
Footnotes / references
Corporate Profile
Grünenthal is a pharmaceutical company headquartered in Aachen in Germany. The company was founded in 1946 as Chemie Grünenthal and has been continuously family-owned. The company was the first to introduce penicillin into the German market in the postwar period, after the Allied Control Council lifted its ban.
Grünenthal became infamous in the 1950s and 1960s for the development and sale of the teratogenic drug thalidomide, marketed as the sleeping pill Contergan and promoted as a morning sickness preventative. Thalidomide caused severe birth defects, miscarriages, and other severe health problems. Though these side effects were proven conclusively in 1959,[1] and 1962,[2] Grünenthal continued marketing the drug well into the 1970s and 1980s.[3]
The company generates more than 50 percent of its income with pain medications such as the drug Tramadol. The company has two offices in Germany as well as subsidiaries in Europe, Latin America, the US, and China. In November 2016, the company acquired Thar Pharmaceuticals [4] and in 2018 Averitas Pharma.[5]
Images
hasselman
Breda 
Levering binnen Nederland ( 3,90 euro verzendkosten )
Levering binnen de EU is mogelijk bij bestellingen vanaf 15 euro plus bijkomende internationale verzendkosten.
Afhalen is niet mogelijk.
- Tous les livres sont en état complet et normal, sauf indication contraire. De petites imperfections comme une page collée ou un nom sur la feuille ne sont pas toujours mentionnés
- Vous gérez directement cette commande avec hasselman
- Après votre commande vous et hasselman recevrez une confirmation par e-mail. Dans l'e-mail que vous pouvez trouver, vous pouvez trouver le nom et l'adresse de hasselman
- L'acheteur paie les frais de livraison, sauf accord contraire
- hasselman peut demander un prépaiement
- Boekwinkeltjes.nl essaie de rapprocher les acheteurs et les vendeurs. Boekwinkeltjes.nl n'est jamais impliqué dans un accord entre l'acheteur et le vendeur. Si vous avez un différend avec un ou plusieurs utilisateurs, vous devez le réparer vous-même. Vous indemnisez Boekwinkeltjes.nl de toute réclamation.